These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 21497434)

  • 1. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update.
    Athanasopoulos A; Chapple C; Fowler C; Gratzke C; Kaplan S; Stief C; Tubaro A
    Eur Urol; 2011 Jul; 60(1):94-105. PubMed ID: 21497434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimuscarinics and bladder outlet obstruction: From a contraindication to an indication?
    Athanasopoulos A
    Neurourol Urodyn; 2010; 29 Suppl 1():S46-50. PubMed ID: 20127792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder.
    Chapple CR; Roehrborn CG
    Eur Urol; 2006 Apr; 49(4):651-8. PubMed ID: 16530611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia.
    Chapple C
    Curr Opin Urol; 2010 Jan; 20(1):43-8. PubMed ID: 19875964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimuscarinic mechanisms and the overactive detrusor: an update.
    Andersson KE
    Eur Urol; 2011 Mar; 59(3):377-86. PubMed ID: 21168951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic.
    Hanuš T; Zámečník L; Doležal T; Karmazínová Z
    Urol Int; 2011; 86(4):407-13. PubMed ID: 21454947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When to use antimuscarinics in men who have lower urinary tract symptoms.
    Lee JY; Kim DK; Chancellor MB
    Urol Clin North Am; 2006 Nov; 33(4):531-7, x. PubMed ID: 17011389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
    Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
    Lee JY; Kim HW; Lee SJ; Koh JS; Suh HJ; Chancellor MB
    BJU Int; 2004 Oct; 94(6):817-20. PubMed ID: 15476515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.
    Kaplan SA; Goldfischer ER; Steers WD; Gittelman M; Andoh M; Forero-Schwanhaeuser S
    Aging Male; 2010 Jun; 13(2):100-7. PubMed ID: 20001469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Male overactive bladder: pharmacotherapy for the male.
    Giannitsas K; Athanasopoulos A
    Curr Opin Urol; 2013 Nov; 23(6):515-9. PubMed ID: 23851386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alfuzosin for the treatment of storage symptoms suggestive of overactive bladder.
    Cho KJ; Kim JC
    Expert Opin Pharmacother; 2012 Jun; 13(8):1143-51. PubMed ID: 22594844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses.
    Buser N; Ivic S; Kessler TM; Kessels AG; Bachmann LM
    Eur Urol; 2012 Dec; 62(6):1040-60. PubMed ID: 22999811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The medical treatment of overactive bladder, including current and future treatments.
    Athanasopoulos A; Cruz F
    Expert Opin Pharmacother; 2011 May; 12(7):1041-55. PubMed ID: 21299469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P; Kaplan S; De Koning Gans HJ; Millard R
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medical treatment of voiding problems in men].
    Andersen JT; Nordling J; Walter S
    Ugeskr Laeger; 2007 May; 169(20):1892-4. PubMed ID: 17553364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK.
    Morant SV; Reilly K; Bloomfield GA; Chapple C
    Int J Clin Pract; 2008 May; 62(5):688-94. PubMed ID: 18355237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.